Clinical effect of inhaled budesonide suspension for the treatment of asthma in children

doi:10.3969/j.issn.2095-3755.2019.03.008

Abstract

Abstract:

Objective To explore the clinical effect of inhalation budesonide suspension (Pulmicort Respules) for the treatment of asthma in children.Methods One hundred and seven children with asthma treated in Shenyang 245 Hospital from May 2017 to May 2019 were included as subjects, among which, 52 cases (2 cases were lost to follow-up) in the control group received conventional basic treatment, and 55 cases (3 cases were lost to follow-up) in the experimental group were given inhalation treatment of budesonide suspension combined with conventional treatment. Then the clinical therapeutic effects as well as the changes in CD4 ⁺ T lymphocytes, C-reactive protein (CRP), interleukin-6 (IL-6), forced expiratory volume in 1 second (FEV₁), and forced vital capacity (FVC) levels between the two groups were compared. Results After 7 days of treatment, the total effective rate of the experimental group (96.2%, 50/52) was significantly higher than that of the control group (80.0%, 40/50), with the significant statistical difference (χ ²=4.94, P<0.05). In addition, after 7 days of treatment, the percentage of CD4 ⁺ T lymphocyte in total lymphocyte ((34.32±4.15) %), the ratio of CD4 ⁺/CD8 ⁺ (1.20±0.28), CRP level ((12.38±2.98) mg/L), and IL-6 level ((54.23±6.54) ng/L) in the experimental group were obviously lower than those in the control group ((45.37±3.08) %, 1.67±0.16, (35.82±7.31) mg/L, and (74.24±8.11) ng/L, respectively), all with the significant statistical differences (t=13.35, 9.10, 18.54, and 11.99, respectively, all P<0.05). Furthermore, after 7 days of treatment, the levels of FEV₁ and FVC in the experimental group ((2.41±0.32) L and (1.45±0.28) L) were remarkably higher than those in the control group ((2.08±0.47) L and (1.23±0.22) L), with the significant statistical differences (t=3.62, and 3.86, both P<0.05). Conclusion Inhalation budesonide suspension is effective for the treatment of children with asthma, which can effectively regulate the levels of CD4 ⁺ T lymphocyte and CD4 ⁺/CD8 ⁺ in children with asthma, improve pulmonary function and accelerate the recovery of children’s condition.

Key words: Asthma, Child, Budesonide, T-lymphocytes, Treatment outcome

ZHANG Hong-hui,HUANG Wei.. Clinical effect of inhaled budesonide suspension for the treatment of asthma in children[J]. Journal of Tuberculosis and Lung Health , 2019, 8(3): 188-191. doi: 10.3969/j.issn.2095-3755.2019.03.008

Figures/Tables 2

组别	CD4⁺(%, $x ˉ$ ±s)		CD8⁺(%, $x ˉ$ ±s)		CD4⁺/CD8⁺( $x ˉ$ ±s)
组别	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组(50例)	47.92±2.37	45.37±3.08	21.02±3.81	27.51±2.58	2.41±0.33	1.67±0.16
研究组(52例)	47.96±2.42	34.32±4.15	21.08±3.76	27.99±3.03	2.43±0.38	1.20±0.28
t值	0.07	13.35	0.07	0.75	0.25	9.10
P值	0.474	0.003	0.475	0.265	0.414	0.006

组别	CRP(mg/L, $x ˉ$ ±s)		IL-6(ng/L, $x ˉ$ ±s)		FEV₁(L, $x ˉ$ ±s)		FVC(L, $x ˉ$ ±s)
组别	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组(50例)	43.17±4.82	35.82±7.31	147.62±13.89	74.24±8.11	1.54±0.28	2.08±0.47	1.08±0.12	1.23±0.22
研究组(52例)	42.89±4.96	12.38±2.98	146.58±14.05	54.23±6.54	1.55±0.31	2.41±0.32	1.07±0.11	1.45±0.28
t值	0.25	18.54	0.33	11.99	0.15	3.62	0.38	3.86
P值	0.412	0.001	0.387	0.003	0.447	0.034	0.369	0.031

References 10

[1]	付伟, 陈乾华 . 哮喘与咳嗽变异性哮喘患者小气道功能障碍特点. 现代仪器与医疗, 2018,24(6):136-138.
[2]	中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 支气管哮喘基层诊疗指南(2018年). 中华全科医师杂志, 2018,17(10):751-762.
[3]	代先慧, 郝月琴 . 支气管哮喘-慢性阻塞性肺疾病重叠、哮喘、慢性阻塞性肺疾病临床特征的对比研究. 临床肺科杂志, 2018,23(7):1306-1310.
[4]	罗劲松, 杨小平, 马春花 . 脾氨肽联合普米克令舒对小儿支气管哮喘的临床疗效及对CD4 +,CD8+,IgE水平的影响 . 现代生物医学进展, 2017,17(26):5058-5061.
[5]	刘东梅 . 吸入糖皮质激素治疗支气管哮喘患者的临床研究进展. 医疗装备, 2017,30(15):196-197.
[6]	宋建伟 . 普米克令舒对小儿哮喘的治疗效果和T淋巴细胞亚群CD4 +、CD8+的影响 . 北方药学, 2017,14(11):32-33.
[7]	洪爽, 吴春青, 王建忠 , 等. 氧驱雾化吸入普米克令舒治疗小儿哮喘急性发作疗效及对肺功能的影响. 中国妇幼保健, 2017,32(6):1207-1210.
[8]	林明相 . 支气管哮喘急性发作期血清C反应蛋白检验的临床分析. 中国医药科学, 2017,7(15):113-115.
[9]	李强, 魏丽娟 . 血清炎性指标在慢性气流受限性疾病中的表达及其临床意义. 临床合理用药杂志, 2018,11(27):174-175.
[10]	张桐 . 18例重症支气管哮喘患者的临床疗效分析. 结核病与肺部健康杂志, 2018,7(1):77-78.

[1]	HUANG Jin-bao, LAN Chang-qing, LYU Xiao, CHEN Lu-lu, WANG Xin-hang, CHEN Yu-rong, HUANG Ming-xiang. Analysis of 23 cases of imported coronavirus disease 2019 [J]. Journal of Tuberculosis and Lung Disease, 2020, 1(3): 213-219.
[2]	Rena·Abulaiti, Kelibiena·Tuerxun, Dilinuer·Wufuer. Research progress on correlation between bronchial asthma and psychological disorders [J]. Journal of Tuberculosis and Lung Disease, 2020, 1(3): 285-288.
[3]	JIN Min-lu, CHANG Yun-qing, QI Feng-ming, GUAN Xiao-gang, ZHENG Guan-hua, ZHAO Yong-hua, LI Zhen-qiang, LI Xiao-sheng, WANG Li-fen, WANG Fang, BAI Yin-jie. Clinical characteristics and effect analysis of 39 cases of 2019 novel Coronavirus-related pneumonia [J]. Journal of Tuberculosis and Lung Disease, 2020, 1(2): 131-135.
[4]	WANG Li-hua, LIU Yan-yan. Clinical analysis of 27 neurobrucellosis cases misdiagnosed as tuberculosis meningitis [J]. Journal of Tuberculosis and Lung Disease, 2020, 1(2): 183-185.
[5]	SONG Min, FANG Wei-jun, HAN Yuan-yuan, FENG Hui-yong. Analysis of CT features of drug-resistant tuberculosis in children [J]. Journal of Tuberculosis and Lung Health, 2020, 9(1): 58-63.
[6]	MAO Yi, WU Gui-hui, CHEN Juan, CHEN Hong-de. Application of lung protective ventilation strategy in mechanical ventilation of patients with pulmonary tuberculosis complicated with HIV infection [J]. Journal of Tuberculosis and Lung Disease, 2020, 1(1): 45-48.
[7]	CHEN Yu,LI Qiao-si,FAN Li-chao,ZHU Ya-juan,LYU Yue-qiu.. Analysis of clinical features and outcome of treatment in 41 children with tuberculous meningitis [J]. Journal of Tuberculosis and Lung Health, 2019, 8(3): 197-202.
[8]	Kui LIU,Ting WU,Wei WANG,Ying PENG,Fei WANG,Tie-niu HE,Cheng-liang CHAI,Xiao-meng WANG,Bin CHEN. Delay in detection of tuberculosis in children under 15 years of age in Zhejiang Province from 2009 to 2018 [J]. Journal of Tuberculosis and Lung Health, 2019, 8(2): 115-120.
[9]	Lian-zhi WANG,Chun-lei ZHANG,Jing ZHANG,Ying-ying LI,Hui JIANG,Lin-chuan LANG,Jun SUN,Lan-wei CUI,Bin-ying JI. Value of GeneXpert MTB/RIF in detection of tuberculosis suspects among children by using gastric juice [J]. Journal of Tuberculosis and Lung Health, 2019, 8(2): 127-132.
[10]	Jing YAO,Xin SHEN,Kai-kan GU,Zhi-hong LI,Zhi-ying HAN,Huai-qing ZHANG,Bing SHEN. The global and national tuberculosis epidemic situation of children and schools [J]. Journal of Tuberculosis and Lung Health, 2019, 8(2): 142-145.
[11]	Juan WANG,Xiang XU,Jing JIANG,Mei-xia. YANG. Analysis on registration and outcome of diabetes mellitus complicated with pulmonary tuberculosis patients in Xuhui District of Shanghai from 2013 to 2017 [J]. Journal of Tuberculosis and Lung Health, 2019, 8(1): 29-32.
[12]	Yan GUO,Yu ZHU,Lin SUN,Xue QI,Xue-meng WAN,Xiao-rong LIU. Clinical characteristics of renal tuberculosis in fourteen children [J]. Journal of Tuberculosis and Lung Health, 2018, 7(4): 251-254.
[13]	Yong FENG,Hong-bin LIANG,Wei-zhong DING. Discussion on surgical treatments for chronic massive tuberculous empyema [J]. Journal of Tuberculosis and Lung Health, 2018, 7(4): 305-310.
[14]	Li-hua ZHENG,Jing-lai YU,Peng SUN,Hong-qing LI,Dong CHEN,Ying-jie YU,Sha NI,Ming XU,Yan CHENG,Chun-guang MA,Chun-yu ZHAO,Na YANG,Gui-jiao LI,Juan. LI. Clinical efficacy analysis of Qingfei Qulao Pill in the treatment of patients with relapsed pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Health, 2018, 7(2): 114-119.
[15]	Guo-fang DENG,Liang. FU. Current status of diagnosis and treatment of tuberculosis complicated with rheumatic diseases [J]. Journal of Tuberculosis and Lung Health, 2018, 7(2): 88-90.